A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

Conditions: Healthy Interventions: Drug: ND-003 40mg; Drug: ND-003 placebo 40mg; Drug: ND-003 80mg; Drug: ND-003 placebo 80mg; Drug: ND-003 160mg; Drug: ND-003 placebo 160mg; Drug: ND-003 240mg; Drug: ND-003 placebo 240mg; Drug: ND-003 300mg; Drug: ND-003 placebo 300mg; Drug: MAD_ND003_Dose 1; Drug: MAD_placebo_Dose 1; Drug: MAD_ND003_Dose 2; Drug: MAD_placebo_Dose 2; Drug: MAD_ND003_Dose 3; Drug: MAD_ placebo_Dose 3; Drug: Food effect_Cohort 1; Drug: Food effect_Cohort 2 Sponsors: Shenzhen NewDEL Biotech, Co., Ltd; Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials